信達生物(01801.HK):達伯舒®第四季度銷售收入達9億元,銷量保持逐季增長良好態勢
格隆匯2月4日丨信達生物(01801.HK)發佈公吿,達伯舒®(信迪利單抗注射液)是由集團與禮來製藥共同開發,並於2019年3月成功推出。2021年第四季度,達伯舒®(信迪利單抗注射液)持續取得令人鼓舞的銷售表現。達伯舒®(信迪利單抗注射液)於2021年第四季度取得有關票面銷售收入約為人民幣9億元,產品銷售量保持逐季增長的良好態勢。此外,達伯舒®(信迪利單抗注射液)順利新增三項一線適應症納入國家醫保目錄(NRDL)。公司在2022年1月1日新醫保目錄及價格正式執行前,於2021年第四季度末,對按照原價格分銷於渠道1中的產品向分銷商予以合計超人民幣3億元的價格調整補償。
目前,達伯舒®(信迪利單抗注射液)成為國內唯一一個擁有包含一線非鱗非小細胞肺癌、一線鱗狀非小細胞肺癌、一線肝癌及至少經過二線系統化療的復發或難治性經典型霍奇金淋巴瘤在內的四項適應症獲批,並均被納入國家醫保的PD-1抑制劑。此外,達伯舒®(信迪利單抗注射液)用於治療一線食管鱗癌的上市申請、用於治療一線胃癌的上市申請,以及用於表皮生長因數受體酪氨酸激酶抑制劑(「EGFR-TKI」)治療失敗的EGFR突變非鱗狀非小細胞肺癌的上市申請已獲中國藥品監督管理局受理審評。
公司相信達伯舒®(信迪利單抗注射液)持續令人鼓舞的銷售表現顯示出其作為抗PD-1抑制劑的高品質領先品牌在中國PD-(L)1市場具有強大的市場潛力,以及公司作為高品質廠商的商業化能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.